Please use this identifier to cite or link to this item:
http://hdl.handle.net/11054/3347| Title: | Salvage therapies for recurrent grade 4 IDH-wildtype glioma: A BRAIN Registry analysis of real-world treatment patterns. |
| Author: | Sanderson, E. Drummond, K. Dowling, A. Bennett, I. Freilich, R. Phillips, C. Ahern, E. Campbell, D. Campbell, R. Harrup, R. Reeves, Simone Collins, I. Jennens, R. Joshi, S. Gan, H. Fay, M. Lynam, J. Lim, Lisi E. Rosenthal, M. Dumas, M. Gibbs, P. Gately, L. |
| Issue Date: | 2026 |
| Publication Title: | Journal of Neuro-Oncology |
| Volume: | 179 |
| Start Page: | 13 |
| Abstract: | Purpose: The prognosis for patients with glioblastoma after failure of first-line therapy is poor. Despite this, the standard of care for patients with recurrent disease is not well-defined. Here we report on the use of salvage therapies in glioblastoma using real-world data. Methods: Data were extracted from the BRAIN Registry for patients diagnosed with glioblastoma (Grade 4, IDH wild-type) between 09/2019 and 01/2024. Only patients who received salvage therapies following a documented date of recurrence/progression were included. Relevant descriptive and intergroup statistics were used, with survival calculated using Kaplan-Meier and Cox regression used for multivariate analyses. Results: 275 patients were identified. Median age was 61 (range:23–88) years, with 56% being ECOG 0–1 at recurrence. Median time to progression was 7.6 months with 65% recurring/progressing during first-line therapy. Systemic therapy (85%) was most utilised with 67% receiving single-agent bevacizumab. Outcomes in this subgroup were similar to clinical trial data. 29% patients underwent re-resection with 58% of these then receiving systemic treatment. Compared with no surgery, patients who underwent re-resection were younger (p = 0.02), of better performance status (p = 0.006) and more likely to have recurred post completing first-line therapy (p = 0.001). Few patients (n = 9) received re-irradiation with median of 15 months between radiation events. Median post-progression survival (PPS) was 9.5 months. After adjustment for confounders, there was no difference in PPS for patients who underwent re-resection versus systemic therapy alone (p = 0.242). The survival differences observed between treatment modalities likely reflect patient factors influencing treatment selection and were impacted by small subgroup sizes. Conclusion: Systemic therapy is most utilised in the salvage setting, predominantly bevacizumab. Certain patient characteristics were associated with re-resection. Re-irradiation was rarely used. Clinical trial number: ACTRN12618001959268. |
| URI: | http://hdl.handle.net/11054/3347 |
| DOI: | https://doi.org/10.1007/s11060-026-05717-x |
| Internal ID Number: | 03299 |
| Health Subject: | GLIOBLASTOMA RECURRENCE TREATMENT PATTERNS SALVAGE THERAPIES |
| Type: | Journal Article Article |
| Appears in Collections: | Research Output |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.